Vericel Corporation (NASDAQ:VCEL – Get Free Report) insider Jonathan Siegal sold 2,732 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $44.90, for a total value of $122,666.80. Following the sale, the insider directly owned 886 shares in the company, valued at approximately $39,781.40. This trade represents a 75.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Vericel Price Performance
VCEL stock traded down $0.58 during trading on Tuesday, hitting $44.49. 743,265 shares of the company traded hands, compared to its average volume of 621,141. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $46.62. The stock’s 50-day simple moving average is $36.33 and its 200 day simple moving average is $35.85. The company has a market cap of $2.27 billion, a PE ratio of 105.93 and a beta of 1.12.
Vericel (NASDAQ:VCEL – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $68.43 million for the quarter, compared to analysts’ expectations of $63.68 million. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The business’s revenue was up 30.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.23) EPS. Research analysts expect that Vericel Corporation will post 0.49 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on VCEL
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Vericel by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 3,584,006 shares of the biotechnology company’s stock valued at $129,060,000 after acquiring an additional 68,368 shares during the period. State Street Corp increased its holdings in Vericel by 12.7% in the 4th quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company’s stock worth $113,933,000 after acquiring an additional 356,680 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in Vericel by 9.3% during the first quarter. Conestoga Capital Advisors LLC now owns 2,463,312 shares of the biotechnology company’s stock worth $79,245,000 after acquiring an additional 208,750 shares during the period. William Blair Investment Management LLC raised its position in Vericel by 0.5% during the fourth quarter. William Blair Investment Management LLC now owns 2,222,107 shares of the biotechnology company’s stock worth $80,018,000 after acquiring an additional 11,178 shares during the period. Finally, Geneva Capital Management LLC lifted its holdings in Vericel by 9.0% during the third quarter. Geneva Capital Management LLC now owns 1,946,305 shares of the biotechnology company’s stock valued at $61,250,000 after purchasing an additional 161,378 shares in the last quarter.
About Vericel
Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.
Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.
Featured Articles
- Five stocks we like better than Vericel
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
